Gaining Momentum: BASi Adds Candace Rohde-Johnson as Director of in Vivo Products and Services
WEST LAFAYETTE, Ind., October 3, 2017 (Newswire.com) - Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi” or the “Company”) today announced the addition of Candace Rohde-Johnson as Director of In Vivo Products and Services.
Ms. Rohde-Johnson will lead BASi’s In Vivo Products and Services Team with a focus on accelerating sales and expanding into new markets, contributing to product growth and innovation, and helping maintain the company’s longstanding commitment to its clients and their drug development success. She will also leverage her marketing experience to help create valuable content for the company’s clients and prospects, and provide surgical training and collaboration in BASi’s state-of-the-art vivarium using their Culex® in vivo sampling systems.
Having previously been a member of the BASi team for nearly a decade, we know Candace well- and highly-regarded her as a competent researcher, exceptionally-skilled animal surgeon, and passionate advocate for our Culex product line.
Jill Blumhoff, BASi Chief Financial Officer and Vice President of Finance
“Having previously been a member of the BASi team for nearly a decade, we know Candace well-and highly-regarded her as a competent researcher, exceptionally-skilled animal surgeon, and passionate advocate for our Culex product line,” said Jill Blumhoff, Chief Financial Officer and Vice President of Finance at BASi. “Candace has a true gift for listening closely to clients and turning their ideas into solutions. She is well-respected in our field and is known for her dedication, collaborative nature, mentorship, and enthusiasm.”
Rohde-Johnson is BASi’s second high-profile hire in recent months as the company further fills out its team of industry experts in contract research services, preclinical PK-PD and preclinical toxicology. With Candace and other key leaders in place, Peter T. Kissinger, BASi Founder and Scientific Adviser, believes that “BASi is well-positioned to further improve the reach of our innovative line of in vivo products and to help our clients optimize their drug discovery and preclinical development efforts.”
Ms. Rohde-Johnson earned a B.S. in Anthropology/Zoology from the University of Michigan in 2003. She has worked in animal research for more than 12 years, beginning in the lab and moving into customer support and management roles. Throughout her career, Candace has worked with clients worldwide to provide training, seminars and workshops focused on improving research results without sacrificing animal welfare.
About Bioanalytical Systems, Inc.
BASi is a pharmaceutical development company providing Preclinical, Toxicological and Bioanalytical contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. The Company’s in vivo automated sampling center is a purpose-built facility including ten in vivo labs, colony rooms for rats and mice with individually ventilated housing systems (IVCs), rodent surgical site, and a wet lab and cage wash facility that is complemented by state-of-the-art cold storage, formulations and bioanalytical facilities. The Company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit www.BASinc.com for more information about BASi.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.
Company Contact:
Jill Blumhoff
Chief Financial Officer &
Vice President of Finance
Phone: 765.497.8381
jblumhoff@BASinc.com
Source: Bioanalytical Systems, Inc.
Related Media
